Clinical trial NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Official title: Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With High Stromal Tumor-infiltrating Lymphocytes (TILs) Score
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Triple-negative Breast Cancer
Keywords: Breast cancer
De-escalation
Immunotherapy
Chemotherapy
Lead sponsor: UNICANCER
Sponsor class: OTHER
Collaborators: name: MSD France
name: SOLTI Breast Cancer Research Group
name: Gustave Roussy, Cancer Campus, Grand Paris
name: Vall Hebron Insitut Recerca
First posted: 2023-10-11
Enrollment: 354
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Cohort of patients with T1b/c N0 M0 TNBC aged \> 40 years with 30% ≤ sTILs \< 50% and those aged ≤ 40 years with 30% ≤ sTILs \< 75%: Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles at adjuvant phase of the treatment; Cohort of patients with T1b/c N0 M0 TNBC aged \> 40 years and sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75%: No treatment will be administered. These patients will undergo standard surveillance every 6 months according to local practice.
Primary purpose: TREATMENT

Brief summary: Triple-negative breast cancer (TNBC) is a group of tumors that occurs mainly in young, premenopausal women and accounts for 10-20% of breast cancers. Over the past decade, the incidence of women diagnosed with early-stage TNBC has significantly increased due to the widespread use of screening mammography. Treatment of patients with localized TNBC mainly involves surgery and (neo)adjuvant chemotherapy with or without radiotherapy. However, the benefit of chemotherapy may be controversial in patients with early-stage TNBC defined by small size and absence of lymph node involvement, and with significant tumor lymphocyte infiltration.

The ETNA study is a phase II trial designed to evaluate a chemotherapy de-escalation strategy in patients with TNBC T1b/c N0M0 and stromal TILs (sTILs) ≥ 30%. ETNA comprises two cohorts defined according to the level of TILs and the age of patients. Patients aged \> 40 years with 30% ≤ sTILs \< 50% and those aged ≤ 40 years with 30% ≤ sTILs \< 75% will be included in the cohort 1 and will receive adjuvant pembrolizumab 200 mg every three weeks for 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles. Patients aged \> 40 years with sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75% will be included in cohort 2 and will not receive adjuvant treatment, they will undergo standard surveillance every six months.

Detailed description: (Neo)adjuvant chemotherapy in breast cancer is associated to long-term persistent QoL deterioration in patients with early breast cancer, with a greater negative impact in patients that were premenopausal at diagnosis. Because triple negative breast cancer (TNBC), which accounts for 10-20% of breast cancers, presents a poorer prognosis as compared to the other subtypes, international guidelines endorse the use of adjuvant chemotherapy from TNBC tumors measuring \> 5 mm. Nevertheless, a number of retrospective studies have reported excellent prognosis for patients with small, lymph node-negative and high TILs TNBC, even without chemotherapy, with 5-year overall survival (OS) of 98%. Findings from multiple data sets consistently demonstrated that TILs represent a robust prognostic and predictive biomarker in early-stage TNBC, being now the first biological prognostic marker for TNBC included in several international guidelines for early-stage disease, such as 2019 St Gallen consensus conference and European Society for Medical Oncology (ESMO) Guidelines for early-stage breast cancer.

In clinical practice, oncologists have taken different approaches in patients with stage I TNBC. While some have de-escalated anthracyclines, other did not held back on the standard chemotherapy options with anthracyclines, taxanes, and cyclophosphamide. Based on unpublished data from the TNBC pooled analysis with sTILs on 2211 patients not treated by systematic therapy, performed at Gustave Roussy, the 5-year distant disease free-survival (DDFS) is 87%, 91%, and 93% for those with stage I and sTILs ≥ 30%, 50%, and 75%, respectively. Given these compelling findings from historical observations, it is reasonable to anticipate that the absolute benefit of chemotherapy would be modest among these patients as their tumors generally exhibit a favorable prognosis, resulting in reduced benefits with the use of adjuvant chemotherapy.

ETNA is a phase II, multicenter, biomarker-driven study that is designed to characterize the clinical course of patients with stage I TNBC and sTILs ≥ 30%.

ETNA includes patients with stage I and sTILs ≥ 30% TNBC in 2 cohorts:

* Cohort 1 will include patients age \> 40 years with 30% ≤ sTILs \< 50% and those aged ≤ 40 years with 30% ≤ sTILs \< 75%. Patients will receive 9 cycles of adjuvant pembrolizumab 200 mg every three weeks for 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles.
* Cohort 2 will include patients aged \> 40 years with sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75% who will undergo standard surveillance (no adjuvant systemic treatments).

Eligibility criteria: Inclusion Criteria:

1. Understand, sign, and date the written informed consent form prior to any protocol- specific procedures performed,
2. Men and women aged ≥ 18 years,
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,
4. Histologically confirmed and radically removed pT1b/c N0M0 TNBC as defined according to AJCC TNM stage-8th version,

   * Histologically documented TNBC (negative HER2, ER, and PgR status). HER2 negativity is defined by local laboratory assessment using in situ hybridization and immunohistochemistry assays as per ASCO/CAP criteria and ER/PgR negativity is defined by local laboratory assessment \< 10% using immunohistochemistry assays,
   * Bilateral and/or multifocal primary tumor is allowed and the tumor with the most advanced T stage should be used to asses for eligibility. If multifocal tumor, a pathologic confirmation of TNBC is required for each focus,
5. Adequately excised breast cancer: subjects must have undergone either breast- conserving surgery or mastectomy/nipple- or skin-sparing mastectomy.

   * For subjects who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. Reresections to ensure no ink on tumor margins are allowed. Subjects with margins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection.
   * For subjects who undergo mastectomy/nipple- or skin-sparing mastectomy, margins must be free of gross residual tumor. It is recommended that subjects should have a negative microscopic margin in accordance with local pathology protocol,
6. Have had sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND) for evaluation of pathologic nodal status.

   Axillary nodal dissection(s) should yield a total of at least six nodes (including the axillary lymph nodes resected at the SLNB plus the lymph nodes collected at the axillary nodal dissection),
7. At least 4 weeks but no more than 12 weeks between definitive breast surgery (or the last surgery with curative intent if additional resection is required for breast cancer) and treatment initiation for cohort 1 and no more than 12 weeks for cohort 2,
8. Centrally assessed TILs score from surgical formalin-fixed paraffin embedded (FFPE) tumor sample, using an H\&E stained diagnostic digital slide, according to the most recent International TILs Working Group guidelines,

   * Cohort 1 will include patients aged \> 40 years with 30% ≤ sTILs \< 50% and those aged

     * 40 years with 30% ≤ sTILs \< 75%
   * Cohort 2 will include patients aged \> 40 years with sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75%
9. Women of childbearing potential have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication for cohort 1 and within 7 days of inclusion for cohort 2,
10. Women of childbearing potential must agree to use protocol-specified method(s) of contraception for 3 years after patient inclusion. Men subjects who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception during trial treatments and for at least 6 months after the last dose of trial treatments.

    Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year,
11. Patients affiliated to the social security system (or equivalent)- France only,
12. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.

    Additional inclusion criteria for subjects of cohort 1:
13. Left ventricular ejection fraction (LVEF) of ≥ 50% as assessed by echocardiogram or cardiac scintigraphy,
14. Demonstrate adequate organ function within 7 days of inclusion

    * Absolute Neutrophil Count (ANC) ≥ 1,500 /µL
    * Platelets ≥ 100,000 /µL
    * Hemoglobin ≥ 9 g/dL
    * Creatinine clearance ≥ 30 mL/min for subject with creatinine levels \> 1.5 x institutional upper limit of normal (ULN)
    * Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN
    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
    * Albumin ≥ 3.0 g/dL
    * Lactate dehydrogenase (LDH) \< 2.5 X ULN
    * International normalized ratio/partial thromboplastin time (INR/PTT) ≤ 1.5 x ULN (unless subject is receiving anticoagulant therapy as long as prothrombin time (PT) or PTT is within therapeutic range of intended use of anticoagulants)
    * Thyroid stimulating hormone (TSH), free T4 (FT4), and free T3 (FT3) within normal ranges
    * Cortisol at 8 AM within normal ranges
    * Lipase and amylase \< 3 ULN
    * Fasting plasma glucose ≤ 120 mg/dl or 6.7 mmol/L
    * Troponin within normal range

Exclusion Criteria:

1. History of invasive malignancy ≤ 3 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer,
2. Having received prior chemotherapy or targeted therapy within the past 12 months,
3. Has a prior history of DCIS and/or LCIS that was treated with any form of systemic, hormonal therapy, or radiotherapy to the ipsilateral breast; subjects who had their DCIS/LCIS treated only with surgery and/or contralateral DCIS treated with radiotherapy are allowed to enter the study,
4. Having received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or with an agent directed to another co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137),
5. Treatment with systemic immunostimulatory agents (including, but not limited to, interferons, interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to inclusion,
6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive medications (including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] alpha agents) within 7 days prior to inclusion:

   * Subjects who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study
   * The use of inhaled corticosteroids and mineralocorticoids is allowed,
7. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment; subjects with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible if:

   * Rash must covers \<10% of body surface area.
   * Disease is well controlled at baseline and requires only low-potency topical Corticosteroids and no acute exacerbations requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or oral corticosteroids occurred within the previous 12 months,
8. Has a known history of Human Immunodeficiency Virus (HIV),
9. Prior allogeneic stem cell or solid organ transplant,
10. Has a known history of active Bacillus Tuberculosis,
11. Patients with any other disease or illness which requires hospitalisation or is incompatible with the trial treatment are not eligible,
12. Pregnant women or breastfeeding or expecting to conceive within the projected duration of the study, from the inclusion visit until the end of the 3 years follow up. Men subjects who engage in heterosexual intercourse and refuse to use protocol-specified method(s) of contraception during trial treatments and for at least 6 months after the last dose of trial treatments,
13. Patients unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial,
14. Person deprived of their liberty or under protective custody or guardianship,
15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

    Additional non-inclusion criteria for subjects of cohort 1:
16. Has cardiac dysfunction as defined by any of the following prior to inclusion:

    * History of NCI-CTCAE v5.0 Grade \> 3 symptomatic congestive heart failure or New York Heart Association (NYHA) criteria Class II,
    * Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or clinically significant valvular disease,
    * Significant symptoms (≥ Grade 2) relating to left ventricular dysfunction or cardiac ischemia,
17. Has a known hypersensitivity (≥ Grade 3) to the components of the study therapy or its analogs,
18. Has received a live vaccine or live-attenuated vaccine within 30 days of the first dose of study treatment,
19. Concurrent active Hepatitis B virus (HBV; defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (HCV; defined as anti-HCV Ab positive and detectable HCV RNA) infection,
20. Severe infections within 4 weeks prior to initiation of study treatment, including, hospitalization for complications of infection, bacteremia, or severe pneumonia,
21. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment; subjects receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection) are eligible,
22. Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during study treatment,
23. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has a current pneumonitis/interstitial lung disease,
24. Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 4 weeks of the first dose of treatment in this current trial.

Primary outcomes:
measure: Distant disease-free survival (DDFS)
timeFrame: 5 year
Secondary outcomes:
measure: Invasive disease-free survival (IDFS)
timeFrame: From inclusion up to 5 year
measure: Distant recurrence-free survival (DRFS)
timeFrame: From inclusion up to 5 year
measure: Overall survival (OS)
timeFrame: From inclusion to death from any cause, up to 5 year
measure: Incidence of Adverse Events
timeFrame: Throughout study completion, up to 5 year
measure: Quality of life questionnaire - Core 30 (QLQ-C30)
timeFrame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years
measure: Quality of Life Questionnaire - Breast cancer module (QLQ-BR23)
timeFrame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years
measure: Quality of Life Questionnaire - Cancer-related fatigue (QLQ-FA12)
timeFrame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years
measure: Hospital anxiety and depression scale (HADS)
timeFrame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie_Site Sud
city: Avignon
country: France
facility: Institut Sainte Catherine
city: Bayonne
country: France
facility: Centre Hospitalier de la Côte Basque
city: Bordeaux
country: France
facility: Institut Bergonié
city: Bordeaux
country: France
facility: Polyclinique Bordeaux Nord Aquitaine
city: Caen
country: France
facility: Centre François Baclesse
city: Clermont-Ferrand
country: France
facility: Pôle Santé Republique
city: Clermont-Ferrand
country: France
facility: Centre Jean Perrin
city: Dijon
country: France
facility: Centre Georges-François Leclerc
city: Levallois-Perret
country: France
facility: Hôpital Franco-Britannique-Fondation Cognacq-Jay
city: Limoges
country: France
facility: CHU de Limoges
city: Lyon
country: France
facility: Centre Léon Bérard
city: Lyon
country: France
facility: Hopital Privé Jean Mermoz
city: Marseille
country: France
facility: Institut Paoli-Calmettes
city: Montpellier
country: France
facility: Institut régional du Cancer de Montpellier
city: Nantes
country: France
facility: Hôpital privé du confluent
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Nîmes
country: France
facility: CHU de Nîmes
city: Pau
country: France
facility: Centre Hospitalier de Pau
city: Plérin
country: France
facility: Hôpital Privé des côtes d'Armor
city: Pontoise
country: France
facility: Hôpital NOVO
city: Quimper
country: France
facility: Centre Hospitalier de Cornouaille
city: Quint-Fonsegrives
country: France
facility: Clinique La Croix du Sud
city: Reims
country: France
facility: Institut Godinot
city: Rennes
country: France
facility: Centre Eugène Marquis
city: Saint-Étienne
country: France
facility: CHU de Saint Etienne
city: Toulouse
country: France
facility: Institut Claudius Regaud
city: Tours
country: France
facility: CHU Bretonneau
city: Vandœuvre-lès-Nancy
country: France
facility: Centre Alexis Vautrin
city: Villejuif
country: France
facility: Gustave Roussy
city: Badalona
country: Spain
facility: Ico Badalona
city: Barcelona
country: Spain
facility: Hospital Vall D'Hebrón
city: Córdoba
country: Spain
facility: Hospital Universitario Reina Sofia
city: El Palmar
country: Spain
facility: Hospital Clinico Universitario Virgen de La Arrixaca
city: Granada
country: Spain
facility: Hospital Universitario Clinico San Cecilio
city: Hospitalet de Llobregat
country: Spain
facility: Ico Hospitalet
city: León
country: Spain
facility: Complejo Asistencial Universitario de Leon
city: Lleida
country: Spain
facility: Hu Arnau de Vilanova Lleida
city: Madrid
country: Spain
facility: Hospital Ramon Y Cajal
city: Madrid
country: Spain
facility: Hospital 12 de Octubre
city: Palma De Mallorca
country: Spain
facility: Hospital Universitari Son Espases
city: Reus
country: Spain
facility: Hospital Sant Joan de Reus
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Del Rocio
city: Valencia
country: Spain
facility: Hospital Clínico Valencia
Study officials:
affiliation: Gustave Roussy, Villejuif, France
name: Elie Rassy, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Gustave Roussy, Villejuif, France
name: Barbara Pistilli, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: HOSPITAL VALL D'HEBRÓN, Barcelona, Spain
name: Mafalda Oliveira, MD
role: PRINCIPAL_INVESTIGATOR
References: